Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01350 (gastrin)
 9,683 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effect of adenosine, adenosine 5'-triphosphate (ATP) and ATP analogs on basal gastric somatostatin-like immunoreactivity (SLI) release was studied using the vascularly perfused rat stomach. The release of gastric SLI was stimulated by adenosine (0.6-60 microM) concentration dependently, while the release of immunoreactive gastrin was inhibited by 1 and 10 microM adenosine. The stimulatory action of adenosine was probably mediated by adenosine receptors because the receptor antagonist, 8-phenyltheophylline, abolished the action of adenosine. In addition, the adenosine-induced release of SLI was not mediated by a cholinergic or beta-adrenergic mechanism, since atropine, hexamethonium or propranolol did not block the action of adenosine. Dipyridamole enhanced the adenosine-stimulated, but not 2-chloroadenosine-induced SLI release. Since the adenosine analog, 2-chloroadenosine, is resistant to the adenosine uptake mechanism, it is likely that adenosine-stimulated release of gastric SLI is due to the activation of extracellular receptors. ATP also stimulated gastric SLI release. The analogs alpha,beta-methyleneadenosine triphosphate and diphosphate, which are resistant to metabolic breakdown, did not stimulate basal SLI release, while gamma,beta-methyleneadenosine triphosphate, which can be metabolized, increased the release of SLI. In addition, the ATP-induced release of SLI was abolished by 8-phenyltheophylline. Therefore, the action of ATP is likely to be a result of its metabolism to adenosine.
 ...
PMID:Augmentation of release of gastric somatostatin-like immunoreactivity by adenosine, adenosine triphosphate and their analogs. 197 32

(-)-Epigallocatechin gallate, (-)-Gossypol; Ad.hIFN-beta, AF-37702, Agatolimod sodium, Agomelatine, Alvocidib hydrochloride, ARC-1779; Belimumab, BIBW-2992, Binodenoson, Bortezomib, Bosutinib, Brivaracetam; Cediranib, Clevidipine, CNTO-328, CP-751871, Curcumin; Darapladib, Deforolimus, Denosumab, Desvenlafaxine succinate, Dipyridamole/prednisolone, Dronedarone hydrochloride, DTPw-HBV/Hib 2.5; Ecogramostim, Elacytarabine, Eltrombopag, Eprodisate sodium; Farnesylthiosalicylic acid, Febuxostat, Fenretinide, Ferumoxytol, FMP2.1/AS02A, Forodesine hydrochloride, FP-0011; HuLuc-63, Human Fibroblast Growth Factor 1; Idraparinux sodium, Indium 111 (111In) ibritumomab tiuxetan, Interleukin-21, Ipilimumab, ISS-1018, ITF-2357; Lapaquistat acetate, Laropiprant, Liposomal vincristine, LY-518674; Masitinib mesylate, MAXY-G34, MGCD-0103, Midostaurin, Mitumprotimut-T, MK-0343, MLN-1202, MM-093, Motexafin gadolinium; NB-001, NB-002, Niacin/laropiprant; Oblimersen sodium, Ocrelizumab, Omacetaxine mepesuccinate; Panobinostat, Patupilone, PBI-1402, Perifosine, PHA-739358, Plerixafor hydrochloride, Prasugrel; Regadenoson, RHAMM R3 peptide, Rilonacept, Rivaroxaban, Romiplostim; Safinamide mesilate, Salinosporamide A, Selenite sodium, Sotrastaurin; Thrombin alfa, Tipifarnib, TRO-19622; Vatalanib succinate, Vernakalant hydrochloride, VRC-WNVDNA017-00-VP; YM-155, Yttrium 90 (90Y) ibritumomab tiuxetan; Zosuquidar trihydrochloride.
 ...
PMID:Gateways to clinical trials. 1859 9